Abstract
This highlight describes novel substituted pyrido-[4,3-d]-pyrimidine compounds as KRAS (Kirsten rat sarcoma viral oncogene homologue) inhibitors. The invention provides details about novel pyrido-[4,3-d]-pyrimidine compounds, their pharmaceutical composition, potential use, and treatment for KRAS-related diseases, such as various cancers.